<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370874</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-DFU-301</org_study_id>
    <nct_id>NCT03370874</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.</brief_title>
  <official_title>Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in
      patients with Diabetic Foot Ulcer, compared to placebo therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental: ALLO-ASC-DFU, Placebo Comparator: Vehicle Sheet, Study type: Interventional,
      Study design: Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center
      Study
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure</measure>
    <time_frame>During 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time taken to complete wound closure between the two groups</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure</measure>
    <time_frame>Follow up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups</measure>
    <time_frame>Follow up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change rates in wound size and depth compared to baseline between the two groups</measure>
    <time_frame>During 12 weeks</time_frame>
    <description>cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations</measure>
    <time_frame>Follow up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Sheet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hydrogel sheet without Allogenic mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC-DFU</intervention_name>
    <description>Application of ALLO-ASC-DFU sheet to diabetic foot ulcer</description>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <other_name>Hydrogel sheet containing allogenic mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vehicle sheet</intervention_name>
    <description>Application of Vehicle sheet to diabetic foot ulcer</description>
    <arm_group_label>Vehicle Sheet</arm_group_label>
    <other_name>Hydrogel sheet without Allogenic mesenchymal stem cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is between 18 and 80 years of age.

          2. Subject is diagnosed with Type I or Type II diabetics and has diabetic foot ulcers for
             longer than 4 weeks at the screening visit.

          3. Foot ulcer size is between 1 cm2 and 25 cm2

          4. Ulcer graded I or II by Wagner grade, and extended to skin, tendon, and subcutaneous
             tissue.

          5. Free of necrotic debris at target ulcer

          6. Around ulcer area blood circulation should be secured to meet one of below criteria;

               -  Blood vessels around the ulcer detected by Doppler Test

               -  0.7 &lt; Ankle Brachial Index(ABI) &lt; 1.3

               -  Transcutaneous Oxygen Pressure, TcPO2 higher than 30 mmHg

          7. Subject is able to give written informed consent prior to study start and to comply
             with the study requirements during study.

        Exclusion Criteria:

          1. Non-diabetic pathophysiologic ulcer.

          2. The ulcer has increased or decreased in size by 30% or more during one week after the
             screening visit.

          3. Subjects requiring intravenous (IV) antibiotics to treat infection.

          4. Current evidence of infection including pus drainage from the wound site.

          5. Subject has a glycated hemoglobin A1c (HbA1c) level of &gt; 15%

          6. Subject's blood sugar is &gt; 450 mg/dl at postprandial.

          7. Subjects with severe renal failure that cannot be managed by renal dialysis.

          8. Subjects with severe hepatic deficiencies.

          9. Subject is Human Immunodeficiency Virus (HIV) positive.

         10. Subject who has allergic or hypersensitive reaction to bovine-derived proteins or
             fibrin glue.

         11. Subject who is pregnant or breast-feeding.

         12. Subjects who are unwilling to use an &quot;effective&quot; method of contraception during the
             study.

         13. Subjects who have a clinically relevant history of alcohol or drugs abuse.

         14. Subjects who are not able to understand the objective of this study or to comply with
             the study requirements.

         15. Subjects who are considered to have a significant disease which can impact the study
             by investigator.

         16. Subjects who are considered not suitable for the study by investigator.

         17. Subjects who had had a history of surgery for malignant tumor within the last five
             years (except carcinoma in situ).

         18. Subjects who are currently or are enrolled in another clinical study within 60 days of
             screening.

         19. Subjects who have undergone wound treatments with growth factors, dermal substitutes,
             or other biological therapies within the last 30 days.

         20. Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or
             cytotoxic agents with unstable dose prior to 4 weeks from screening.

         21. Subjects not comply with off-loading procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Kyu Han, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki-Won Young, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eulji General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junpyo Hong, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donghyeok Shin, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junhyeong Kim, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chan Kang, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iljae Lee, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Changsik Park, MD. Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-Kyu Han, MD. Ph D.</last_name>
    <phone>82-2-2626-3333</phone>
    <email>pshan@kumc.or.kr</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

